Indeed, Muraoka et al. (2020) proposed M6a, together with ANX5, VGF, and ACTZ as a biomarker for monitoring AD progression from CSF samples (Muraoka et al., 2020). This evidence concerns the gene GPM6A and Alzheimer disease.